GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Abstract Text:

Vincent G Brichard,Diane Lejeune,Vincent G Brichard,Diane Lejeune,Vincent G Brichard,Diane Lejeune,Vincent G Brichard,Diane Lejeune,

From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches aimed at targeting these antigens have already been the subject of clinical studies. In this field, the GSK Biologicals' approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and has the potential to be applied to all tumor types.

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Publishing Authors By Initials

VG Brichard,D Lejeune,VG Brichard,D Lejeune,VG Brichard,D Lejeune,VG Brichard,D Lejeune,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Journal Published:

PUBLICATION TYPE: Review

Journal: Vaccine

VOLUME: 25 Suppl 2

Page Numbers: B61-71

Journal Abbreviation: Vaccine

ISSN: 0264-410X

DAY: 27

MONTH: Sep

YEAR: 2007

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8406899

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.

AFFILIATION: Cancer Immunotherapeutics R&D, GlaxoSmithKline Biologicals, Rue de l'Institut, Rixensart, Belgium. vincent.brichard@gskbio.com

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Vaccine

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development Related Publications

• ABILOCO: a Rasch-built 13-item questionnaire to assess locomotion ability in stroke patients.
• Association of prophage antiterminator Q alleles and susceptibility to food-processing treatments applied to Escherichia coli O157 in laboratory media.
• Beneficial effects of almitrine bismesylate on pulmonary gas exchange in COPD.
• Benign pedunculated esophageal tumors; report of a case.
• Current status of melanoma chemotherapy and immunotherapy.
• Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study.
• Effect of speed on kinematic, kinetic, electromyographic and energetic reference values during treadmill walking.
• Effects of chronic median nerve compression at the wrist on sensation and manual skills.
• Francis Ernest LeJeune 1894--1977.
• GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.
• Isolation of Escherichia coli O157:H7 strains that do not produce Shiga toxin from bovine, avian and environmental sources.
• Letter: Hematuria following thiabendazole.
• Not Available
• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
• Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
• Pull-through technique for palmar digital neurectomy: forty-one horses (1998-2004).
• Salmonella enterica isolated from wildlife at two Ohio rehabilitation centers.
• Study designs in neurosurgery.
• The impact of surgery on the course of melanoma.
• The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients.
• Transoral surgery for early carcinoma of the larynx.
• Usefulness of MR Imaging for the Assessment of Nonophthalmic Paraclinoid Aneurysms.
• [A proposition for the management of aneurisms]
• [Eugéne Jamot and Emile Lejeune. Historical pages]
• [Hospital infections in the maternity department at Brest Hospital over a period from 2000 to 2005.]
• [Non-traumatic intracranial hemorrhage]
• [Simultaneous detection of HBs antigen and antiHBs antibody by a radioimmunologic method]
• [Study of endemic malaria in the villages along the banks of the Kwango River.]
• [The treatment of alveolar hypoventilation in cardiorespiratory failure in kyphotic patients.]
• [Use of a new antibiotic, citrinin, in treatment of tropical ulcer.]